DDInter1376 DDInter142
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 and EMA approval on 24 September 2020.
Avapritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Avapritinib {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Avapritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Avapritinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Avapritinib may lead to a major life threatening interaction when taken with Golimumab
Avapritinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Avapritinib may lead to a major life threatening interaction when taken with Flurbiprofen